js","6773","static/chunks/6773-061975b7a13f2526.js","3763","static/chunks/3763-5031c38f7a5044a1.js","4777","static/chunks/4777-7fa79cea095b0267.js","5071","static/chunks/5071-1aaad1643fd0f3d9.js","8631","static/chunks/8631-6612905842e66f05.js","3956","static/chunks/3956-445a540d184d91db.js","7952","static/chunks/7952-ee4e3ac10fbedfda.js","512","static/chunks/512-bcb290eabed856c4.js","7759","static/chunks/7759-79303bb83414620d.js","5422","static/chunks/5422-29b2c0073e365b16.js","2507","static/chunks/2507-ee0144f0fb20ac76.js","8492","static/chunks/8492-f17ab3216fe361f9.js","2785","static/chunks/2785-116580b35f1bb322.js","8368","static/chunks/8368-438d4be7dd683dfc.js","9080","static/chunks/9080-238ac880c12fda6b.js","7072","static/chunks/7072-530245caea10a4c5.js","3192","static/chunks/3192-edaab38c2fdeb6ab.js","3077","static/chunks/3077-c474095a61bd66c9.js","8234","static/chunks/8234-bf699f647ee74353.js","4589","static/chunks/4589-5b05633819f33918.js","229","static/chunks/229-db5ac014176aaf5b.js","5458","static/chunks/app/dashboard/episodes/%5Bid%5D/page-249b9fb0028b9980.js"],"EpisodeRecommend"] 23:T547,

Psychiatric drug development has had major wins over the past year-and-a-half — think Karuna Pharmaceuticals' $14 billion takeout by Bristol Myers Squibb and the subsequent launch of a new schizophrenia therapy — but targeted neuropsychiatric drug development is still in its infancy. On a special edition of the BioCentury This Week podcast, BioCentury’s editors detail the promise for the space and break down what recent setbacks for key players mean for next steps in the clinic. The team is joined by special guest Peter Schueler, SVP of drug development solutions, neurosciences, at ICON, who delivers takeaways from this month’s the ECNP Roadmap Meeting on Precision Psychiatry in Frankfurt and a recent white paper by ICON. This episode of BioCentury This Week was sponsored by ICON Biotech

Ep. 276 - Precision Neuropsychiatry Spotlight With ICON's Peter Schueler

BioCentury This Week